PGGM Investments purchased a new stake in Edwards Lifesciences Co. (NYSE:EW – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 2,172 shares of the medical research company’s stock, valued at approximately $208,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of EW. DSM Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter worth $28,000. Crewe Advisors LLC acquired a new stake in Edwards Lifesciences in the 1st quarter valued at $28,000. Turtle Creek Wealth Advisors LLC purchased a new position in Edwards Lifesciences in the fourth quarter valued at about $34,000. Riverview Trust Co purchased a new position in Edwards Lifesciences in the first quarter valued at about $34,000. Finally, Pingora Partners LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter worth about $38,000. 79.46% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Edwards Lifesciences
In other news, CEO Bernard J. Zovighian purchased 580 shares of Edwards Lifesciences stock in a transaction dated Monday, May 6th. The stock was bought at an average price of $85.74 per share, with a total value of $49,729.20. Following the completion of the acquisition, the chief executive officer now owns 3,268 shares in the company, valued at approximately $280,198.32. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Bernard J. Zovighian sold 8,617 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $87.68, for a total value of $755,538.56. Following the completion of the transaction, the chief executive officer now directly owns 68,218 shares of the company’s stock, valued at approximately $5,981,354.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bernard J. Zovighian bought 580 shares of the business’s stock in a transaction on Monday, May 6th. The shares were acquired at an average cost of $85.74 per share, for a total transaction of $49,729.20. Following the purchase, the chief executive officer now directly owns 3,268 shares in the company, valued at $280,198.32. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 30,099 shares of company stock worth $2,680,879. 1.29% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
Read Our Latest Stock Report on Edwards Lifesciences
Edwards Lifesciences Stock Down 1.7 %
EW stock opened at $60.83 on Friday. The firm has a fifty day moving average price of $85.32 and a two-hundred day moving average price of $86.49. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.87. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The firm has a market cap of $36.64 billion, a price-to-earnings ratio of 26.22, a PEG ratio of 2.57 and a beta of 1.11.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business had revenue of $1.63 billion during the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter in the prior year, the firm earned $0.66 EPS. The company’s revenue for the quarter was up 6.7% compared to the same quarter last year. Research analysts predict that Edwards Lifesciences Co. will post 2.71 EPS for the current year.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Featured Articles
- Five stocks we like better than Edwards Lifesciences
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Short Selling: How to Short a Stock
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.